Literature DB >> 23139408

Redefining functional MYCN gene signatures in neuroblastoma.

Jason Matthew Shohet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23139408      PMCID： PMC3511077          DOI： 10.1073/pnas.1217598109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

Authors:  Katleen De Preter; Joëlle Vermeulen; Benedikt Brors; Olivier Delattre; Angelika Eggert; Matthias Fischer; Isabelle Janoueix-Lerosey; Cinzia Lavarino; John M Maris; Jaume Mora; Akira Nakagawara; André Oberthuer; Miki Ohira; Gudrun Schleiermacher; Alexander Schramm; Johannes H Schulte; Qun Wang; Frank Westermann; Frank Speleman; Jo Vandesompele
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.

Authors:  Nunzio Iraci; Daniel Diolaiti; Antonella Papa; Antonio Porro; Emanuele Valli; Samuele Gherardi; Steffi Herold; Martin Eilers; Roberto Bernardoni; Giuliano Della Valle; Giovanni Perini
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

Review 3.  N-myc and noncoding RNAs in neuroblastoma.

Authors:  Jochen Buechner; Christer Einvik
Journal:  Mol Cancer Res       Date:  2012-08-30       Impact factor: 5.852

4.  Survival and late effects in children with stage 4 neuroblastoma.

Authors:  Thomas Perwein; Herwig Lackner; Petra Sovinz; Martin Benesch; Sandrin Schmidt; Wolfgang Schwinger; Christian Urban
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

5.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

6.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Authors:  Linda J Valentijn; Jan Koster; Franciska Haneveld; Rachida Ait Aissa; Peter van Sluis; Marloes E C Broekmans; Jan J Molenaar; Johan van Nes; Rogier Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

7.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.

Authors:  Kristina A Cole; Edward F Attiyeh; Yael P Mosse; Michael J Laquaglia; Sharon J Diskin; Garrett M Brodeur; John M Maris
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

10.  SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.

Authors:  Glenn M Marshall; Pei Y Liu; Samuele Gherardi; Christopher J Scarlett; Antonio Bedalov; Ning Xu; Nuncio Iraci; Emanuele Valli; Dora Ling; Wayne Thomas; Margo van Bekkum; Eric Sekyere; Kacper Jankowski; Toby Trahair; Karen L Mackenzie; Michelle Haber; Murray D Norris; Andrew V Biankin; Giovanni Perini; Tao Liu
Journal:  PLoS Genet       Date:  2011-06-16       Impact factor: 5.917
View more
  2 in total

1.  Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma.

Authors:  Valerio Maggio; Marco Chierici; Giuseppe Jurman; Cesare Furlanello
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

Review 2.  Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma.

Authors:  Alfred Buhagiar; Duncan Ayers
Journal:  Anal Cell Pathol (Amst)       Date:  2015-07-14       Impact factor: 2.916
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.